Tissue samples, tissue arrays, cells, microorganisms, probes and services for your research.
Payment methods we support:
✭ Invoice / Purchase Order
✭ Credit card
Patient-derived organoid (PDO) model is a 3D cell-based scaffolding technology that enables patient-derived cancer cells to be cultured in laboratories, and used for testing against a panel of approved drugs and new drug candidates.
Despite the improvements in early detection, reduced prevalence of risk factors, and advances in targeted therapy, cancer still remains the most significant health burden worldwide, especially colorectal cancer and breast cancer. In order to develop new treatment strategies, we need to test therapy ideas or drugs in models, which should be faithfully recapitulate the biology of the patient's tumor so they can help us predict what therapies or drugs will work in patients in the clinic. Patient-derived xenograft (PDX) models represent the gold standard of making patient tumors into pre-clinical models. Nevertheless, of the drugs that do enter clinical testing, the majority fails due to lack of effectiveness and the presence of side effects. Clearly, there is an urgent need to develop more effective and economical models to improve current pre-clinical testing.
By incorporating cells derived from PDX models and validated 3D cell culture platform, Creative Bioarray established and generated multiple patient-derived organoid (PDO) models. The models create a unique opportunity for high throughput 3D screening platforms to reduce and replace PDX model use.
Creative Bioarray PDO model advantages
Generation of PDO model
Fig.1 Development of a high-throughput drug screening assay utilizing PDO models
Quotation and ordering
If you have any special needs in establishment or application of patient-derived organoid (PDO) models, please contact us at email@example.com or 1-631-626-9181 for this special service. Let us know what you need and we will accommodate you. We look forward to working with you in the future.
|1.||Wetering, M.; et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015, 161: 933–945.|
|2.||Xie, B.Y.; Wu, A.W. Organoid culture of isolated cells from patient‑derived tissues with colorectal cancer. Chinese Medical Journal. 2016, 129(20): 2469-2475.|